ストックスクリーナーアプリを入手
0.2798
2.00%
-0.0057
前日終値:
$0.2855
開ける：
$0.2813
24時間の取引高:
323.49K
Relative Volume:
0.21
時価総額：
$8.44M
収益：
-
当期純損益:
$-98.79M
株価収益率:
-0.0856
EPS:
-3.27
ネットキャッシュフロー:
$-51.66M
1週間 パフォーマンス:
-15.60%
1か月 パフォーマンス:
-28.11%
6か月 パフォーマンス:
-89.90%
1年 パフォーマンス:
-95.07%
1日の値動き範囲:
$0.2603
$0.2899
1週間の範囲:
$0.2603
$0.3373
52週間の値動き範囲:
$0.2603
$7.2225
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1935 | 408.35M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.50 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4399 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.79 | 120.14M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.0439 | 52.60M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-06-05 | ダウングレード | Goldman | Neutral → Sell |
| 2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-10-14 | ダウングレード | Truist | Buy → Hold |
| 2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 開始されました | Mizuho | Buy |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-04 | 開始されました | SunTrust | Buy |
| 2020-04-21 | 開始されました | Goldman | Buy |
| 2020-01-27 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
RLMD stock touches 52-week low at $0.28 amid market challenges - Investing.com Australia
A significant driver of top-line growth: Relmada Therapeutics Inc (RLMD) - SETE News
Relmada acquires new Tourette syndrome treatment asset - MSN
Relmada Therapeutics Inc [RLMD] Investment Guide: What You Need to Know - Knox Daily
RLMD stock’s current quarter earnings estimates: What analysts predict? - US Post News
Closing Strong: Relmada Therapeutics Inc (RLMD) Ends at 0.31, Down -9.62 from Last Close - The Dwinnex
Relmada Therapeutics Inc’s Shares Reel: -90.69% Quarterly Revenue Decline Amid 9.33M Market Cap - The InvestChronicle
A company insider recently bought 51,407 shares of Relmada Therapeutics Inc [RLMD]. Should You Buy? - Knox Daily
Mizuho maintains Neutral on Relmada stock, sees deal potential - MSN
The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina - News & Insights
Relmada in-licenses Tourette syndrome drug from Asarina - The Pharma Letter
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - SETE News
Relmada acquires Tourette’s therapy rights from Asarina - Yahoo Finance
Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News
Relmada acquires new Tourette syndrome treatment asset By Investing.com - Investing.com Nigeria
Mizuho maintains Neutral on Relmada stock, sees deal potential By Investing.com - Investing.com Australia
Relmada Therapeutics Acquires Sepranolone From Asarina Pharma For Potential TS Treatment - Nasdaq
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - Marketscreener.com
Relmada Therapeutics acquires Sepranolone from Asarina Pharma - TipRanks
Relmada Therapeutics (RLMD) Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - StreetInsider.com
Groundbreaking Tourette Treatment Shows 69% QoL Improvement in Clinical TrialRelmada's Latest Acquisition - StockTitan
Relmada Therapeutics Acquires Sepranolone for CNS Portfolio - TipRanks
Relmada Therapeutics Inc (RLMD) Stock: Navigating a Year of Volatility - The InvestChronicle
Relmada Therapeutics Acquires Potential Therapy For Tourette Syndrome From Asarina Pharma AB - Marketscreener.com
A stock that deserves closer examination: Relmada Therapeutics Inc (RLMD) - US Post News
Relmada Therapeutics Inc (RLMD) may enjoy gains as insiders got busy in the recent days - Knox Daily
Investor’s Delight: Relmada Therapeutics Inc (RLMD) Closes Weak at 0.34, Down -2.61 - The Dwinnex
RLMD stock touches 52-week low at $0.34 amid sharp annual decline - Investing.com Canada
Relmada Therapeutics Inc (NASDAQ:RLMD) Has Made The 2.86% Recovery, Could Gain Another -1962.86% Ahead - Marketing Sentinel
Relmada Therapeutics (NASDAQ:RLMD) Receives Notification from Nasdaq Regarding Minimum Bid Price Compliance - Defense World
Relmada Therapeutics faces potential Nasdaq delisting - MSN
Geode Capital Management LLC Increases Stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Relmada appoints new COO, freezes executive pay - Investing.com
Relmada appoints new COO, freezes executive pay By Investing.com - Investing.com UK
Relmada Therapeutics Appoints COO and Updates Executive CompensationRELMADA THERAPEUTICS, INC. (NASDAQ: RLMD) recently announced a significant update regarding its leadership team and executive compensation structure. According to a rec - Defense World
Relmada Therapeutics Strengthens Leadership with New COO - TipRanks
US Penny Stocks To Watch In January 2025 - Simply Wall St
RLMD stock touches 52-week low at $0.35 amid market challenges - Investing.com Canada
Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021 - BioSpace
Relmada stock hits 52-week low at $0.43 amid market challenges - Investing.com Australia
Relmada stock hits 52-week low at $0.43 amid market challenges By Investing.com - Investing.com South Africa
Relmada seeking strategic options, stock climbs 5% - MSN
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - The Eastern Progress Online
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
Relmada Therapeutics Inc (RLMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
| CASAMENTO CHARLES J | Director |
Sep 09 '24 |
Buy |
2.56 |
13,000 |
33,280 |
13,000 |
| Shenouda Maged | Chief Financial Officer |
Sep 11 '24 |
Buy |
2.95 |
24,120 |
71,154 |
88,335 |
| Shenouda Maged | Chief Financial Officer |
Sep 10 '24 |
Buy |
2.73 |
21,118 |
57,652 |
64,215 |
| Shenouda Maged | Chief Financial Officer |
Sep 09 '24 |
Buy |
2.55 |
8,194 |
20,895 |
43,097 |
| Kelly Paul Edward | Director |
Sep 09 '24 |
Buy |
2.59 |
25,000 |
64,750 |
212,295 |
0.53%
0.33%
大文字化:
|
ボリューム (24 時間):